Red Cat Announces Pricing of Public Offering of Common Stock

SALT LAKE CITY, May 12, 2026 (GLOBE NEWSWIRE) — Red Cat Holdings, Inc. (Nasdaq: RCAT) (“Red Cat” or “Company”), a U.S.-based provider of advanced all-domain drone and robotic solutions for defense and national security, announced today the pricing of an underwritten public offering at a price to the public of $9.40 per share. Red Cat is selling 23,936,171 shares of its common stock. The gross proceeds from the offering to the Company are expected to be approximately $225.0 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about May 14, 2026, subject to customary closing conditions. In addition, Red Cat has granted the underwriters a 30-day option to purchase up to an additional 3,590,425 shares of its common stock at the public offering price, less underwriting discounts and commissions.

The Company intends to use net proceeds from the offering for general corporate purposes and continued acceleration of strategic growth initiatives, including, but not limited to, acquisitions or business expansion, research and development, capital expenditures and working capital.

Evercore ISI and BofA Securities are acting as the joint lead bookrunners for the offering. Needham & Company and Northland Capital Markets are acting as co-managers for the offering.

The shares of common stock are being offered by Red Cat pursuant to an automatically effective shelf registration statement that was filed with the Securities and Exchange Commission (the “SEC”) on May 12, 2026. The offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC and is available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus can be obtained, when available, from Evercore Group L.L.C., 55 East 52nd Street, New York, New York 10055, by telephone at (888) 474-0200, or by email at [email protected] or BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001, or by e-mail at [email protected]. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Red Cat Holdings, Inc.

Red Cat (Nasdaq: RCAT) is a U.S.-based provider of advanced all-domain drone and robotic solutions for defense and national security. Through its wholly owned subsidiaries, Teal Drones and FlightWave Aerospace, Red Cat develops American-made hardware and software that support military, government, and public safety operations across air, land, and sea. Its Family of Systems, led by Black Widow™, delivers unmatched tactical capabilities in small, unmanned aircraft systems (sUAS). Expanding into the maritime domain through Blue Ops, Inc., Red Cat is also innovating in uncrewed surface vessels (USVs), delivering integrated platforms designed to enhance safety and multi-domain mission effectiveness.

Safe Harbor Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Such statements include, but are not limited to, statements relating to the exercise by the underwriters of an option to purchase additional shares and Red Cat’s intended use of proceeds from the offering. Forward-looking statements are based on Red Cat Holdings, Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Form 10-K filed with the SEC on March 19, 2026 and the Form 10-Q filed with the SEC on May 7, 2026, Red Cat’s preliminary prospectus supplement filed with the SEC and the other filings that Red Cat makes with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Red Cat undertakes no duty to update such information except as required under applicable law.

Contact:

INVESTORS:
Ankit Hira
Solebury Strategic Communications for Red Cat Holdings, Inc.
E-mail: [email protected]

NEWS MEDIA:
Peter Moran
Phone: (347) 880-2895
Email: [email protected]



SES AI Corporation Securities Fraud Class Action Result of Weak Revenue Guidance and 37% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

NEW YORK and NEW ORLEANS, May 12, 2026 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until June 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against SES AI Corporation (NYSE: SES) (“SES” or the “Company”), if they purchased or otherwise acquired the Company’s securities between January 29, 2025 and March 4, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Massachusetts.

What You May Do

If you purchased securities of SES and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-ses/?prs=globe to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by June 26, 2026.

>>>

CLICK HERE

for more information

About the Lawsuit

SES and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.  

The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company overstated its business outlook by exaggerating the potential results of agreements with companies that had limited or no operational capacity; (ii) the company created the appearance of revenue by purchasing services tied to its own Molecular Universe transactions; (iii) despite its optimistic growth statements, SES AI faced significant logistics constraints in Q4 2025 that materially impacted revenue for that quarter; (iv) these issues raised serious doubts about SES AI’s 2026 growth prospects, which were later confirmed by weaker-than-expected revenue guidance for 2026; and (v) as a result, the Company’s statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

The case is Patel v. SES AI Corporation, et al., Case No. 26-cv-11894.

>>>To Learn More, Click

HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click

HERE

Contact:

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner
[email protected] 
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn



Super Micro Computer, Inc. Notice of May 26, 2026 Application Deadline for Class Action Lawsuits – Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

NEW YORK CITY and NEW ORLEANS, May 12, 2026 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Super Micro Computer, Inc. (“Super Micro” or the “Company”) (NasdaqGS: SMCI) of class action securities lawsuits.

CLASS DEFINITION: The lawsuits seeks to recover losses on behalf of investors of Super Micro who were adversely affected by alleged securities fraud between February 2, 2024 and March 19, 2026. Follow the link below to get more information and be contacted by a member of our team:

https://ksfcounsel.com/cases/nasdaqgs-smci-2/?prs=globe

Super Micro investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://ksfcounsel.com/cases/nasdaqgs-smci-2/?prs=globe to learn more.

>>>

CLICK HERE

for more information

CASE DETAILS: According to the Complaint, Super Micro and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On March 19, 2026, post-market, the U.S. Department of Justice announced the unsealing of an indictment against three individuals associated with the Company, Yih-Shyan Liaw (the Company’s co-founder, director, and Senior Vice President of Business Development), Ruei-Tsang Chang (“a general manager in the [Super Micro’s] Taiwan office),” and Ting-Wei Sun (“a third-party broker and fixer”), for engaging in a “scheme to divert massive quantities of servers housing U.S. artificial intelligence technology to customers in China” violating U.S. export control laws, in order to “drive sales and generate revenues in violation of U.S. law” and enabled the sale of “approximately $2.5 billion worth of servers” between 2024 and 2025. On this news, the price of Super Micro’s shares fell $10.26, or 33.3%, to close at $20.53 per share on March 20, 2026.

The first-filed case is Bhuva v. Super Micro Computer, Inc., et al., No. 26-cv-02606. A subsequent case, City of Hialeah Employees Retirement Systemv. Super Micro Computer, Inc., et al., No. 26-cv-3018, expanded the class period.

WHAT TO DO? If you invested in Super Micro and suffered a loss during the relevant time frame, you have until May 26, 2026 to request that the Courts appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.

>>>To Learn More, Click

HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click

HERE

Contact:

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn



LKQ Corporation Notice of June 22, 2026 Application Deadline for Class Action Lawsuit – Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

NEW YORK and NEW ORLEANS, May 12, 2026 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in LKQ Corporation (“LKQ” or the “Company”) (NasdaqGS: LKQ) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of LKQ Corporation who were adversely affected by alleged securities fraud between February 27, 2023, and July 23, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://www.ksfcounsel.com/cases/nasdaqgs-lkq/?prs=globe

LKQ investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-lkq/?prs=globe to learn more.

>>>

CLICK HERE

for more information

CASE DETAILS: According to the Complaint, LKQ and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. The claims against Defendants arise from misrepresentations related to the Company’s acquisition of FinishMaster, completed in August 2023, and subsequent integration.

On July 24, 2025, the Company reported second-quarter adjusted earnings that missed analyst expectations and significantly cut its full-year guidance. Among other things, the Company disclosed that its Wholesale North America segment’s margin performance continued to decline, with the Company missing EBITDA targets by approximately $20 million and suffering a year-over-year decline of 11% primarily due to increased competition from others in the industry. On this news, the price of LKQ’s shares fell by 17.8%. or $6.88 per share.

The case is City of Miami General Employees’ & Sanitation Employees’ Retirement Trust v. LKQ Corporation, No. 26-cv-00498.

WHAT TO DO? If you invested in LKQ and suffered a loss during the relevant time frame, you have until June 22, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.

>>>To Learn More, Click

HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click

HERE

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn



Faraday Future EAI Data Factory Signs First Sales Order, Closing the Data Commercialization Loop and Advancing the “Three-in-One” EAI Ecosystem Strategy

Faraday Future EAI Data Factory Signs First Sales Order, Closing the Data Commercialization Loop and Advancing the “Three-in-One” EAI Ecosystem Strategy

  • As the first U.S. company to deliver both humanoid and bionic robots, FF holds a significant first-mover advantage in building a “Device sales – real-world deployment – data collection – Brain model tuning – real-world Brain model updates” data closed loop in the U.S.

  • The EAI (Embodied AI) Data Factory comprises Centralized and Decentralized components and, powered by FF’s proprietary data engine, refines massive real-world raw data into high-value structured action assets directly usable for robot training, establishing a high-margin, asset-light, and recurring-purchase closed-loop data business model.

  • Going forward, the Data Factory will continue to build capabilities for efficient, large-scale data collection, and structured processing, transforming low-cost raw data from real-world deployments into high-quality training data through advanced post-processing. At the appropriate time, FF also plans to open source select data capabilities to contribute to the advancement of the Physical AI industry.

LOS ANGELES–(BUSINESS WIRE)–
Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future,” “FF,” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today announced that its Data Factory Business Unit has signed its first sales order. As a key pillar of FF’s “Three-in-One” EAI ecosystem strategy spanning Device, Brain, and Data, the Data Factory’s launch closes the EAI ecosystem’s data commercialization loop and continues to strengthen the Device-Data-Brain flywheel effect.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512044099/en/

Faraday Future EAI Data Factory Signs First Sales Order, Closing the Data Commercialization Loop and Advancing the “Three-in-One” EAI Ecosystem Strategy

Faraday Future EAI Data Factory Signs First Sales Order, Closing the Data Commercialization Loop and Advancing the “Three-in-One” EAI Ecosystem Strategy

The Data Factory consists of two components: Centralized and Decentralized. The planned Centralized Data Factory supplies the foundational training data required for the base version of the EAI Brain, reinforcing the foundation for model iteration. The Decentralized Data Factory uses low-barrier distributed data collection to disrupt the traditional custom-built data collection approach and is tightly integrated with the real-world deployment of EAI Devices, enabling data to continuously flow back from real-world scenarios into the EAI Brain and driving ongoing evolution of model capabilities.

Building on this architecture, the Company is constructing a “Device sales – real-world deployment – decentralized data collection – Brain model tuning – real-world Brain model updates” data closed loop. As the first U.S. company to deliver both humanoid and bionic robots, FF holds a significant first-mover advantage in building this closed loop in the U.S.

On the product and technology side, the Data Factory leverages FF’s proprietary data engine (Data OS) to refine internet data and low-cost distributed collection data at scale into high-value structured action assets directly usable for robot training, completing the critical leap from unstructured raw data to structured training data. On the commercial side, the Company is building a high-margin, asset-light, and recurring-purchase closed-loop data business model around data services, standardized data products, and subscription offerings. Beyond supporting the closed loop of the “Three-in-One” EAI ecosystem, data produced by the Data Factory can also be sold externally to generate revenue. Within two months of launching the Data Factory, the Company has completed the initial build-out of the Decentralized Data Factory and concluded the signing of its first order, laying the foundation for scaled expansion ahead.

“The formal establishment of the Data Factory is not just the realization of a key link within our ‘Three-in-One’ EAI ecosystem strategy. It also signals that FF is building core infrastructure for the Physical AI era,” said Chris Chen, Co-CEO of FF AI-Robotics. “If the EAI Brain is the engine, data is the fuel that powers its continuous evolution. Through the coordination of our Centralized and Decentralized Data Factories, we are turning every real-world Device deployment into the driving force for upgrading Brain capabilities. We look forward to working with global ecosystem partners to build the Data Factory into critical data infrastructure that advances the Physical AI industry.”

Looking ahead, alongside scaling its operations and external sales, the Data Factory will develop the capability to convert low-cost real world raw data into high-quality training data through post-processing, further expanding data production scale. At the appropriate time, FF will also open source select data capabilities to contribute to the Physical AI industry. The continued build-out and expansion of the Data Factory will steadily amplify the “Device-Data-Brain” flywheel effect, rapidly converting FF’s first delivery first-mover advantage into a sustainably leading position and further solidifying FF’s strategic standing as a global leader in the EAI ecosystem.

About Faraday Future

Founded in 2014, Faraday Future (FF) is a U.S.-based Physical AI ecosystem company dedicated to reshaping the future of robotics and mobility solutions through AI innovation and technologies. FF focuses on two major product strategies within the Embodied AI (EAI) robotics business: EAI humanoid and bionic robots, and EAI automotive-focused robots. By building a Three-in-One ecosystem of “Device, Data, EAI Brain & Open-Source and Open Platform,” FF aims to create an evolutionary flywheel: scaled device delivery, data collection and training, continuous evolution of the EAI Brain, stronger product capability, and even larger-scale delivery and deployment. Through this flywheel, FF seeks to maximize its commercial value and lead to the advancement of Physical AI. For more information, please visit Faraday Future’s official website: https://www.ff.com/

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “plan to,” “expect,” “will,” “should,” “future,” “potential,” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements, which include statements regarding the future development and scaling of FF’s Data Factory, the continued build-out of FF’s “Three-in-One” EAI ecosystem strategy, future external sales of Data Factory output and related revenue generation, the planned development of post-processing capabilities to convert low-cost internet data into high-quality model-training data, the future open-sourcing of select data capabilities, the ongoing evolution of the EAI Brain, and FF’s strategic positioning within the global EAI ecosystem, involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, which could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include, among others: the Company’s ability to maintain its listing on Nasdaq; the availability of sufficient share capital to execute on its strategy, which the Company currently lacks; the agreement of stockholders to substantially increase the Company’s share capital, which could result in substantial additional dilution; demand for the Company’s robotics products; competition in the robotics industry, which includes companies with far superior experience, funding and name recognition; the Company’s reliance on a single OEM for most of its robotics products; the Company’s ability to get the planned robotics products to comply with all applicable U.S. rules and regulations; the ability of the robotics OEM to timely supply robotics to the Company; tariff uncertainty for imported products, particularly from China; the ability of the U.S. Department of Commerce to review, condition, or prohibit robotics-related transactions with a China OEM; demand from automobile dealers for robotics products; the Company’s ability to maintain its listing on Nasdaq; the Company’s ability to timely regain compliance with Nasdaq’s $1.00 minimum bid price requirement; that the Company’s common stock will be suspended from trading on Nasdaq if the closing price of its Class A common stock is $0.10 or less for 10 consecutive trading days; the availability of sufficient share capital to execute on its strategy, which the Company currently lacks; the agreement of stockholders to substantially increase the Company’s share capital, which could result in substantial additional dilution; the Company’s ability to continue as a going concern and improve its liquidity and financial position; the Company’s ability to pay its outstanding obligations; the Company’s ability to remediate its material weaknesses in internal control over financial reporting and the risks related to the restatement of previously issued consolidated financial statements; the Company’s limited operating history and the significant barriers to growth it faces; the Company’s history of losses and expectation of continued losses; the success of the Company’s payroll expense reduction plan; the Company’s ability to execute on its plans to develop and market its vehicles and robots and the timing of these development programs; the Company’s estimates of the size of the markets for its vehicles and robots and cost to bring those vehicles to market; the Company’s ability to cover future warranty claims; the success of other competing manufacturers; current and potential litigation involving the Company; the Company’s ability to receive funds from, satisfy the conditions precedent of and close on the various financings described elsewhere by the Company; the result of future financing efforts, the failure of any of which could result in the Company seeking protection under the Bankruptcy Code; the Company’s indebtedness; the Company’s ability to use its “at-the-market” program; insurance coverage; general economic and market conditions impacting demand for the Company’s products; potential negative impacts of a reverse stock split; potential cost, headcount and salary reduction actions may not be sufficient or may not achieve their expected results; circumstances outside of the Company’s control, such as natural disasters, climate change, health epidemics and pandemics, terrorist attacks, and civil unrest; risks related to the Company’s operations in China; the success of the Company’s remedial measures taken in response to the Special Committee findings; the Company’s dependence on its suppliers and contract manufacturer; the Company’s ability to develop and protect its technologies; the Company’s ability to protect against cybersecurity risks; and the ability of the Company to attract and retain employees, any adverse developments in existing legal proceedings or the initiation of new legal proceedings, and volatility of the Company’s stock price. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s Form 10-K filed with the SEC on March 31, 2026; and other documents filed by the Company from time to time with the SEC.

Investors: [email protected]

Investors (Chinese): [email protected]

Media: [email protected]

KEYWORDS: California China United States North America Asia Pacific

INDUSTRY KEYWORDS: Robotics Automotive Manufacturing Technology Manufacturing Other Technology Software Artificial Intelligence

MEDIA:

Photo
Photo
Faraday Future EAI Data Factory Signs First Sales Order, Closing the Data Commercialization Loop and Advancing the “Three-in-One” EAI Ecosystem Strategy
Logo
Logo

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

  • Who is Involved: ImmunityBio, Inc. (NasdaqGS: IBRX) investors that purchased between January 19, 2026 and March 24, 2026
  • When to Act: Deadline to file Lead Plaintiff applications is May 26, 2026
  • Basis: ImmunityBio shares fell on FDA warning letter over cancer therapy claims in advertisement

NEW YORK CITY and NEW ORLEANS, May 12, 2026 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until May 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against ImmunityBiopurchased or otherwise acquired the Company’s securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.

What You May Do

If you purchased securities of ImmunityBio and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://ksfcounsel.com/cases/nasdaqgs-ibrx-2/?prs=globe to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by May 26, 2026.

>>>

CLICK HERE

for more information

About the Lawsuit

ImmunityBio and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.  

On March 24, 2026, a warning letter dated March 13, 2026, from the U.S. Food and Drug Administration to CEO Richard Adcock was made public, stating that a television advertisement and podcast misrepresented Anktiva and resulted in its distribution violating the Federal Food, Drug, and Cosmetic Act. The letter also reportedly noted that the violations “are concerning from a public health perspective because the promotional communications create a misleading impression that Anktiva, a treatment for a certain type of bladder cancer, can cure and even prevent all cancer.” On this news, the price of ImmunityBio’s shares fell $1.98 per share, or 21%, to close at $7.42 per share on March 24, 2026.

The case is Douglas v. ImmunityBio, Inc., et al., No. 26-cv-03261.

>>>To Learn More, Click

HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click

HERE

Contact:

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn



Gemini Space Station, Inc. Notice of May 18, 2026 Application Deadline for Class Action Lawsuit – Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

NEW YORK and NEW ORLEANS, May 12, 2026 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Gemini Space Station, Inc. (“Gemini” or the “Company”) (NasdaqGS: GEMI) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors who purchased or otherwise acquired Gemini Class A common stock pursuant and/or traceable to the Company’s September 12, 2025 initial public offering (“IPO”), and/or Gemini securities between September 12, 2025 and February 17, 2026 (the “Class Period”). Follow the link below to get more information and be contacted by a member of our team:


https://www.ksfcounsel.com/cases/nasdaqgs-gemi/?prs=globe

Gemini investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-gemi/?prs=globe to learn more.

>>>


CLICK HERE


for more information

CASE DETAILS: According to the Complaint, Gemini and certain of its executives are charged with failing to disclose material information in connection with its Offering Documents in Support of its IPO and/or during the Class Period, violating federal securities laws.

The alleged false and misleading statements and/or omissions include, but are not limited to, that: (i) the Company had overstated the viability of its core business as a crypto platform; (ii) the Company had overstated its commitment to and/or the viability of growing its business through expanding its international operations; (iii) accordingly, the Company’s post-IPO financial and business prospects were overstated; (iv) all of the foregoing raised a non-speculative risk that the Company was poised for an expensive and disruptive restructuring; and (v) as a result, the Offering Documents and defendants’ public statements throughout the class period were materially false and misleading at all relevant times.

The case is Methvin v. Gemini Space Station, Inc., et al., No. 26-cv-02261.

WHAT TO DO? If you invested in Gemini and suffered a loss during the relevant time frame, you have until May 18, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.

>>>To Learn More, Click


HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click


HERE

Contact:

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn



AEP ANNOUNCES PRICING OF COMMON STOCK OFFERING WITH A FORWARD COMPONENT

PR Newswire

COLUMBUS, Ohio, May 12, 2026 /PRNewswire/ — American Electric Power (Nasdaq: AEP) today announced the pricing of a registered underwritten offering of 20,472,442 shares of its common stock at a price to the public of $127.00 per share. Subject to certain conditions, all shares are expected to be borrowed by the forward counterparties (as defined below) (or their respective affiliates) from third parties and sold to the underwriters and offered in connection with the forward sale agreements described below. BofA Securities, Goldman Sachs & Co. LLC and Morgan Stanley are acting as lead book-running managers for this offering. Barclays, Citigroup, J.P. Morgan, Mizuho, MUFG, Scotiabank and Wells Fargo Securities are also acting as joint book-running managers and Guggenheim Securities, KeyBanc Capital Markets, RBC Capital Markets, TD Securities and Truist Securities are acting as co-managers for this offering.

In connection with the offering, AEP entered into forward sale agreements with each of Bank of America, N.A, Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC (the “forward counterparties”) under which AEP agreed to issue and sell to the forward counterparties an aggregate of 20,472,442 shares of its common stock. In addition, the underwriters of the offering have been granted a 30-day option to purchase up to an additional 3,070,866 shares of AEP’s common stock upon the same terms. If the underwriters exercise their option to purchase additional shares, AEP expects to enter into additional forward sale agreements with the forward counterparties with respect to the additional shares.

Settlement of the forward sale agreements is expected to occur on or prior to May 31, 2028. AEP may, subject to certain conditions, elect cash settlement or net share settlement for all or a portion of its rights or obligations under the forward sale agreements.

If AEP elects physical settlement of the forward sale agreements, it expects to use the net proceeds for general corporate purposes, which may include capital contributions to its utility subsidiaries, acquisitions and/or repayment of debt.

The offering is made under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission. This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any such jurisdiction. The offer may be made only by means of a prospectus and the related prospectus supplement. Copies of these documents may be obtained by contacting:

  • BofA Securities by email at [email protected], or by mail at NC1-022-02-25, 201 North Tryon Street, Charlotte, NC  28255-0001, Attention: Prospectus Department;
  • Goldman Sachs & Co. LLC by telephone at (866) 471-2526, by email at [email protected], or by mail at Attention: Prospectus Department, 200 West Street, New York, New York 10282; or
  • Morgan Stanley & Co. LLC by mail at Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014

ABOUT AEP
American Electric Power (Nasdaq: AEP) is committed to improving our customers’ lives with reliable, affordable power. We plan to invest $78 billion from 2026 through 2030 to enhance service for customers and support the growing energy needs of our communities. Our nearly 18,000 employees operate and maintain the nation’s largest electric transmission system with 40,000 line miles, along with more than 252,000 miles of distribution lines to deliver energy to 5.6 million customers in 11 states. AEP also is one of the nation’s largest electricity producers with approximately 32,000 megawatts of diverse owned and contracted generating capacity. We are focused on safety and operational excellence, creating value for our stakeholders and bringing opportunity to our service territory through economic development and community engagement. Our family of companies includes AEP Ohio, AEP Texas, Appalachian Power (in Virginia, West Virginia and Tennessee), Indiana Michigan Power, Kentucky Power, Public Service Company of Oklahoma, and Southwestern Electric Power Company (in Arkansas, Louisiana, east Texas and the Texas Panhandle). AEP also owns AEP Energy, which provides innovative competitive energy solutions nationwide. AEP is headquartered in Columbus, Ohio. For more information, visit aep.com.

This report made by the Registrants contains forward-looking statements, and for the Registrants other than Parent, this report contains forward looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements in this document are presented as of the date of this document. Except to the extent required by applicable law, management undertakes no obligation to update or revise any forward-looking statement. Among the factors that could cause actual results to differ materially from those in the forward-looking statements are: changes in economic conditions, electric market demand and demographic patterns in AEP’s service territory; the economic impact of increased global conflicts and trade tensions, and the adoption or expansion of economic sanctions, tariffs, trade restrictions or changes in trade policy; inflationary or deflationary interest rate trends; new legislation or regulations adopted in the states in which we operate or federal legislation or regulations adopted that alters the regulatory framework or that prevents the timely recovery of costs and investments; volatility and disruptions in financial markets precipitated by any cause, including fiscal and monetary policy or instability in the banking industry; particularly developments affecting the availability or cost of capital to finance new capital projects and refinance existing debt; the availability and cost of funds to finance working capital and capital needs, particularly (a) if expected sources of capital such as proceeds from the sale of tax credits and anticipated securitizations do not materialize or do not materialize at the level anticipated, and (b) during periods when the time lag between incurring costs and recovery is long and the costs are material; changing demand for electricity, including large load contractual commitments; the risks and uncertainties associated with wildfires, including damages caused by wildfires, the extent of each Registrant’s liability in connection with wildfires, investigations and outcomes associated with legal proceedings, demands or similar actions, inability to recover wildfire costs through insurance or through rates and the impact on financial condition and the reputation of each Registrant; the impact of extreme weather conditions, natural disasters and catastrophic events such as storms, hurricanes, wildfires and drought conditions that pose significant risks including potential litigation and the inability to recover significant damages and restoration costs incurred; limitations or restrictions on the amounts and types of insurance available to cover losses that might arise in connection with natural disasters, wildfires or operations; the cost of fuel and its transportation, the creditworthiness and performance of parties who supply and transport fuel and the cost of storing and disposing of used fuel, including coal ash and SNF; the availability of fuel and necessary generation capacity and the performance of generation plants; the ability to recover fuel and other energy costs through regulated or competitive electric rates; the ability to plan for, develop, construct, acquire, or integrate a broad range of generation and energy storage resources, as well as related transmission and distribution infrastructure, including obtaining necessary regulatory approvals, permits, and incentives; complying with cost caps and other regulatory or contractual requirements; and recovering associated costs and earning an appropriate return while meeting reliability, affordability, environmental, and customer–service obligations; the disruption of AEP’s business operations due to impacts of economic or market conditions, costs of compliance with potential government regulations, electricity usage, supply chain issues, customers, service providers, vendors and suppliers caused by natural disasters or other events; construction and development risks associated with the completion of the 2026-2030 capital investment plan, including shortages or delays in labor, materials, equipment or parts; prolonged or recurring U.S. federal government shutdowns could adversely affect AEP’s operations, regulatory approvals, financial performance and could cause volatility in the capital markets which may interrupt our access to capital; new legislation, litigation or government regulation, including changes to tax laws and regulations, oversight of nuclear generation, evolving environmental standards, energy commodity trading and new or modified requirements related to emissions of sulfur, nitrogen, mercury, carbon, soot or PM and other substances that could impact the continued operation, cost recovery and/or profitability of generation plants and related assets; the impact of tax legislation or associated Department of Treasury guidance, including potential changes to existing tax incentives, on capital plans, results of operations, financial condition, cash flows or credit ratings; the risks before, during and after generation of electricity associated with the fuels used or the by-products and wastes of such fuels, including coal ash and SNF; timing and resolution of pending and future rate cases, negotiations and other regulatory decisions, including rate or other recovery of new investments in generation, distribution and transmission service and environmental compliance; resolution of litigation or regulatory proceedings or investigations; the ability to efficiently manage and recover operation, maintenance and development project costs; prices and demand for power generated and sold in wholesale markets; changes in technology, including new, developing, alternative or distributed sources of generation and energy storage; the ability to recover through rates any remaining unrecovered investment in generation units that may be retired before the end of their previously projected useful lives; volatility and changes in markets for coal and other energy-related commodities, particularly changes in the price of natural gas; the impact of changing expectations and demands of customers, regulators, investors and stakeholders, including development, adoption, and use of AI by us, our customers and our third party vendors and evolving expectations related to sustainability; customer affordability considerations may impact regulatory recovery outcomes and future rate design; changes in utility regulation, policies, methodologies for evaluating and approving load interconnection, and the allocation of costs within RTOs including ERCOT, PJM and SPP and the impacts of potential market changes within those RTOs; changes in the creditworthiness of the counterparties with contractual arrangements, including participants in the energy trading market; actions of rating agencies, including changes in ratings impacting the cost of debt; geopolitical developments continue to create uncertainty in global energy markets and have contributed to increased volatility in fuel supply and pricing.  Shifts in global market conditions and broader supply-chain pressures may influence natural gas prices, power-generation economics and customer demand patterns; the impact of volatility in the capital markets on the value of the investments held by the pension, OPEB and nuclear decommissioning trust funds and a captive insurance entity and the impact of such volatility on future funding requirements; accounting standards periodically issued by accounting standard-setting bodies; the ability to successfully defend against cybersecurity threats; other risks and unforeseen events, including wars and military conflicts, the effects of terrorism (including increased security costs), embargoes, labor strikes impacting material supply chains, global information technology disruptions and other catastrophic events; the ability to attract and retain the requisite work force and key personnel, including senior management.  

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/aep-announces-pricing-of-common-stock-offering-with-a-forward-component-302770271.html

SOURCE American Electric Power

Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress

ROCKVILLE, Md. and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, integrated biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for cancers and other diseases, announced today that 17 clinical advances of its core assets will be featured at the 31st Congress of the European Hematology Association (EHA2026), including 8 poster presentations. The abstracts feature data from ongoing clinical studies encompassing Olverembatinib (HQP1351), China’s first approved third-generation BCR-ABL inhibitor, and Lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor. The EHA2026 Congress will convene in Stockholm, Sweden, from June 11 to 14, 2026.

As one of the most authoritative and influential international academic meetings in hematology, the EHA Congress aggregates hematology professionals from around the world to share the latest research advances and breakthrough clinical data.

Key abstracts of accepted poster presentations include:

UPDATED EFFICACY AND SAFETY OF OLVEREMBATINIB (HQP1351) AS SECOND-LINE THERAPY IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)

  • Abstract #: PS1733
  • Presentation Time: Saturday, June 13, 18:45 – 19:45 CEST
  • First Author: Weiming Li, MD, Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

EFFICACY OF OLVEREMBATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) WITH PRIOR RESISTANCE TO PONATINIB OR ASCIMINIB AND ASXL1 MUTATIONS

  • Abstract #: PS1727
  • Presentation Time: Saturday, June 13, 18:45 – 19:45 CEST
  • First Author: Elias Jabbour, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center

UPDATED RESULTS OF POLARIS-1 (PART 1), A GLOBAL REGISTRATIONAL PHASE 3 STUDY: OLVEREMBATINIB COMBINED WITH LOW-INTENSITY CHEMOTHERAPY IN NEWLY DIAGNOSED PH+ ALL

  • Abstract #: PS1479
  • Presentation Time: Saturday, June 13, 2026, 18:45–19:45 CEST
  • First Author: Suning Chen, The First Affiliated Hospital of Soochow University

CORRELATION OF BASELINE CHARACTERISTICS WITH PROGNOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) TREATED WITH LISAFTOCLAX (APG-2575) IN A PIVOTAL PHASE 2 STUDY

  • Abstract #: PS1713
  • Presentation Time: Saturday, June 13, 18:45 – 19:45 CEST
  • First Author: Keshu Zhou, Henan Cancer Hospital

SAFETY AND PRELIMINARY EFFICACY OF OLVEREMBATINIB (HQP1351) COMBINED WITH LISAFTOCLAX (APG-2575) IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY (R/R PH+ ALL): RESULTS OF A PHASE 1B STUDY

  • Abstract #: PS1473
  • Presentation Time: Saturday, June 13, 18:45 – 19:45 CEST
  • First Author: Jingliao Zhang, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

All abstracts (including Posters Presentation and Publication Only) are available on the EHA website.

* Olverembatinib and Lisaftoclax are currently under investigation and have not yet been approved by the FDA in the US.

About Ascentage Pharma

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, next-generation kinase inhibitors, and protein degraders.

The Company’s first approved product, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an FDA-cleared registrational Phase III trial, called POLARIS-2, of Olverembatinib for CML, as well as registrational Phase III trials for patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.

The Company’s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA-cleared GLORA-4 study in patients with newly diagnosed higher risk MDS.

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Cautionary note regarding forward-looking statements” in its Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on April 16, 2025, the sections headed “Forward-looking Statements” and “Risks Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited where the Company’s ordinary shares are listed it has made or it makes from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company’s management.

As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

Investor Relations:

Stella Yang
Ascentage Pharma
[email protected] 
+1 (301) 792-6286

Stephanie Carrington
ICR Healthcare
[email protected]
+1 (646) 277-1282

Media Relations:

Sean Leous
ICR Healthcare
[email protected]
+1 (646) 866-4012



Pan American Silver to Host Investor Day on June 1, 2026

Pan American Silver to Host Investor Day on June 1, 2026

VANCOUVER, British Columbia–(BUSINESS WIRE)–Pan American Silver Corp. (NYSE: PAAS) (TSX: PAAS) (“Pan American“) will host an Investor Day on Monday, June 1, 2026 in Toronto, Ontario from 1:00 to 4:00 pm ET during which Pan American’s executive management team will provide detailed presentations on Pan American’s strategy, operations, growth projects and exploration activities. The event will include a question-and-answer session with management.

Webcast details:

Date: Monday, June 1, 2026

Time: 1:00 pm ET

Registration link: https://reg.lumiengage.com/pan-american-silver-ir-day/reg-en/Site/Register

The presentation slides and a recording of the webcast will be available at https://panamericansilver.com/invest/events-and-presentations/.

About Pan American Silver

Pan American is a leading producer of silver and gold in the Americas, operating mines in Canada, Mexico, Peru, Brazil, Bolivia, Chile and Argentina. We also own a 44% joint venture interest in the producing Juanicipio mine in Mexico, a 100% interest in the Escobal mine in Guatemala that is currently not operating, and we hold interests in exploration and development projects. We have been operating in the Americas for over three decades, earning an industry-leading reputation for sustainability performance, operational excellence and prudent financial management. We are headquartered in Vancouver, B.C. and our shares trade on the New York Stock Exchange and the Toronto Stock Exchange under the symbol “PAAS”.

Learn more at panamericansilver.com

Follow us on LinkedIn

For more information:

Siren Fisekci

VP, Investor Relations & Corporate Communications

Ph: 604-806-3191

Email: [email protected]

KEYWORDS: Africa Australia/Oceania United States Canada North America Australia

INDUSTRY KEYWORDS: Mining/Minerals Natural Resources

MEDIA:

Logo
Logo